Gene · 10498
Papers2,160
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
101 to 120 of 2,160
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| CARM1-induced lncRNA NEAT1 synchronously activates MYCN and GalNAcT-I to accelerate the progression of neuroblastoma. | Gene | 2025 | 39675397 | PubTator, text mining | PubMed |
| RPF2 and CARM1 cooperate to enhance colorectal cancer metastasis via the AKT/GSK-3β signaling pathway. | Exp Cell Res | 2025 | 39674359 | PubTator, text mining | PubMed |
Small-Molecule Modulators Targeting Coactivator-Associated Arginine Methyltransferase 1 (CARM1) as Therapeutic Agents for Cancer Treatment: Current Medicinal Chemistry Insights and Emerging Opportunities. | J Med Chem | 2025 | 39506904 | PubTator, text mining | PubMed |
| USP4/CARM1 Axis Promotes the Malignant Transformation of Breast Cancer Cells by Upregulating SLC7A11 Expression. | Clin Breast Cancer | 2025 | 39500657 | PubTator, text mining | PubMed |
| PRMT4 Reduced Erastin-Induced Ferroptosis in Nasopharyngeal Carcinoma Cisplatin-Resistant Cells by Nrf2/GPX4 Pathway. | J Environ Pathol Toxicol Oncol | 2025 | 39462450 | PubTator, text mining | PubMed |
| CARM1 accelerates the growth of liver cancer cells by enhancing ARAF. | Genes Dis | 2025 | 39415943 | PubTator, text mining | PubMed |
| Looping forward: exploring R-loop processing and therapeutic potential. | FEBS Lett | 2025 | 38844597 | PubTator, text mining | PubMed |
| Repression of PRMT activities sensitize homologous recombination-proficient ovarian and breast cancer cells to PARP inhibitor treatment. | bioRxiv | 2025 | 38826355 | PubTator, text mining | PubMed |
| Investigation of ITGB3 Heterogeneity to Overcome Trastuzumab Resistance in HER2-Positive Breast Cancer. | Biology (Basel) | 2024 | 39857240 | PubTator, text mining | PubMed |
| CARM1-mediated OGT arginine methylation promotes non-small cell lung cancer glycolysis by stabilizing OGT. | Cell Death Dis | 2024 | 39715739 | PubTator, text mining | PubMed |
| Chromatin accessibility: biological functions, molecular mechanisms and therapeutic application. | Signal Transduct Target Ther | 2024 | 39627201 | PubTator, text mining | PubMed |
| Redox-sensitive epigenetic activation of SUV39H1 contributes to liver ischemia-reperfusion injury. | Redox Biol | 2024 | 39603205 | PubTator, text mining | PubMed |
| Arginine methylation-dependent TRIM47 stability mediated by CARM1 promotes the metastasis of hepatocellular carcinoma. | Cell Death Discov | 2024 | 39567506 | PubTator, text mining | PubMed |
| The L27 domain of MPP7 enhances TAZ-YY1 cooperation to renew muscle stem cells. | EMBO Rep | 2024 | 39496834 | PubTator, text mining | PubMed |
| Non-cytotoxic levels of resveratrol enhance the anticancer effects of cisplatin by increasing the methyltransferase activity of CARM1 in human cancer cells. | Phytomedicine | 2024 | 39476485 | PubTator, text mining | PubMed |
| An Adenosine Analogue Library Reveals Insights into Active Sites of Protein Arginine Methyltransferases and Enables the Discovery of a Selective PRMT4 Inhibitor. | J Med Chem | 2024 | 39361813 | PubTator, text mining | PubMed |
| Biochemical Properties of CARM1: Impact on Western Blotting and Proteomic Studies. | ACS Omega | 2024 | 39346878 | PubTator, text mining | PubMed |
| The NRF2-CARM1 axis links glucose sensing to transcriptional and epigenetic regulation of the pentose phosphate pathway in gastric cancer. | Cell Death Dis | 2024 | 39266534 | PubTator, text mining | PubMed |
| Blocking CXCR4-CARM1-YAP axis overcomes osteosarcoma doxorubicin resistance by suppressing aerobic glycolysis. | Cancer Sci | 2024 | 39073190 | PubTator, text mining | PubMed |
| Mechanism and application of feedback loops formed by mechanotransduction and histone modifications. | Genes Dis | 2024 | 39071110 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/10498/papers?page=6